PD-1 inhibitor treatment in a penile cancer patient with MMR/MSI status heterogeneity: A case report

Penile cancer is a rare malignant disease. Paclitaxel combined with platinum is often used as a first-line chemotherapeutic regimen for late-stage penile cancer, and there is no standard second-line treatment. Clinical trials of immunotherapy for penile cancer are ongoing. There are no reports on PD...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, YunYi, Zhang, XiaoLing, Zhang, Ying, Li, WeiLing, Hu, WenQing, Zong, Liang, Zhao, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Immunotherapeutics – Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746458/
https://www.ncbi.nlm.nih.gov/pubmed/36162043
http://dx.doi.org/10.1080/21645515.2022.2121122

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746458/
https://www.ncbi.nlm.nih.gov/pubmed/36162043
http://dx.doi.org/10.1080/21645515.2022.2121122

Ejemplares similares